Drugs / RNA anti-CD19 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02277522 | Oct 2014 → Nov 2016 | Hodgkins lymphoma | University of Pennsylvania | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNA anti-CD19 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02277522 ↗ |
| Known as | CART19 | “we used nonviral RNA CART19 cells” PMID 29925499 ↗ Jun 2018 |
| Known as | RNA CART19 | “we used nonviral RNA CART19 cells” PMID 29925499 ↗ Jun 2018 |
| Action | Deplete | “eradicating CD19+ B cells within the TME” PMID 29925499 ↗ Jun 2018 |
| Modality | Cell therapy | “CAR-modified T cells are being investigated in many settings” PMID 29925499 ↗ Jun 2018 |
| Route | Intravenous | “intravenously administered” NCT02277522 ↗ |
| Target | CD19 | “using anti-CD19-directed CAR-modified T cells (CART19)” PMID 29925499 ↗ Jun 2018 |